Licensing opportunity
Scientists at the Friedrich Miescher Institute in Switzerland have proposed treating cancer by down-regulating the targets frizzled-4 and/or frizzled-1, following their discovery that frizzled-1 and frizzled-4 are over-expressed in cancer.
The frizzled family of receptors are involved in the Wnt signalling pathway, a complex network of proteins that is involved in embryogenesis and cancer.
The researchers say that frizzled-1 and frizzled-4 could also be deployed as biomarkers, both for diagnosis and for stratification of patients in clinical trials.
Both exclusive and non-exclusive license licenses are available.
For more information, visit the project’s page at: http://www.fmi.ch/html/licensing_opportunities/patents.html?id=56
Receive the Funding Newswire [full access requires a subscription] each Tuesday, our Policy Bulletin each Thursday, and news about bridging Europe’s east-west innovation gap twice a month in The Widening. 
A unique international forum for public research organisations and companies to connect their external engagement with strategic interests around their R&D system.
